Cleared Traditional

K131173 - FIA Blood Glucose Monitoring System (G2) (FDA 510(k) Clearance)

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K131173 · Hmd Biomedical, Inc. · Chemistry device

Download Printable Device Report (PDF)

Optimized for regulatory review, auditing and printing

Sep 2014

Decision

511d

Days

Class 2

Risk

K131173 is an FDA 510(k) clearance for the FIA Blood Glucose Monitoring System (G2). Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Hmd Biomedical, Inc. (Xinpu Township, Hsinchu County, TW). The FDA issued a Cleared decision on September 18, 2014 after a review of 511 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Hmd Biomedical, Inc. devices

Submission Details

510(k) Number	K131173 FDA.gov
FDA Decision	Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received	April 25, 2013
Decision Date	September 18, 2014
Days to Decision	511 days
Submission Type	Traditional
Review Panel	Chemistry (CH)
Summary	Summary PDF
Third-party Review	No - reviewed directly by FDA

Regulatory Context

Review time vs. panel average

423d slower than avg

Panel avg: 88d · This submission: 511d

Pathway characteristics

Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code	NBW System, Test, Blood Glucose, Over The Counter
Device Class	Class 2 - Special Controls
CFR Regulation	21 CFR 862.1345

What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.